US 11,938,184 B2
Compositions and methods for treating Crohn's Disease and related conditions and infections
Gaurav Agrawal, Manly (AU)
Assigned to Gaurav Agrawal, Manly (AU)
Filed by Gaurav Agrawal, Manly (AU)
Filed on Mar. 16, 2021, as Appl. No. 17/203,687.
Application 17/203,687 is a continuation of application No. 16/392,274, filed on Apr. 23, 2019, granted, now 10,946,091, issued on Mar. 16, 2021.
Application 16/392,274 is a continuation in part of application No. 15/483,702, filed on Apr. 10, 2017, granted, now 10,376,578, issued on Aug. 13, 2019.
Application 15/483,702 is a continuation of application No. 14/405,384, granted, now 9,616,121, issued on Apr. 11, 2017, previously published as PCT/AU2013/000587, filed on Jun. 3, 2013.
Claims priority of application No. 2012902307 (AU), filed on Jun. 4, 2012.
Prior Publication US 2021/0299254 A1, Sep. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A23C 9/123 (2006.01); A23G 3/36 (2006.01); A23G 4/06 (2006.01); A23G 4/12 (2006.01); A23G 9/32 (2006.01); A23G 9/36 (2006.01); A61K 31/133 (2006.01); A61K 31/4164 (2006.01); A61K 31/435 (2006.01); A61K 31/496 (2006.01); A61K 31/498 (2006.01); A61K 31/7048 (2006.01); A61K 33/00 (2006.01); A61K 39/00 (2006.01); A61K 39/40 (2006.01)
CPC A61K 39/39533 (2013.01) [A23C 9/123 (2013.01); A23G 3/36 (2013.01); A23G 3/364 (2013.01); A23G 4/06 (2013.01); A23G 4/12 (2013.01); A23G 9/32 (2013.01); A23G 9/36 (2013.01); A61K 31/133 (2013.01); A61K 31/4164 (2013.01); A61K 31/435 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/7048 (2013.01); A61K 33/00 (2013.01); A61K 39/3955 (2013.01); A61K 39/40 (2013.01); A61K 2039/505 (2013.01); Y02A 50/30 (2018.01)] 24 Claims
 
1. A method for treating or ameliorating a Crohn's Disease, a complication of a Crohn's Disease, or a Crohn's Disease-related fistulae, comprising administering to an individual in need thereof a therapeutic combination comprising:
(1) at least one anti-TNFα composition or drug; or at least one composition or drug capable of down-modulating or down-regulating a TNFα activity; and
(2) at least two anti-Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agents.